CR20210514A - Use of reboxetine to treat narcolepsy - Google Patents
Use of reboxetine to treat narcolepsyInfo
- Publication number
- CR20210514A CR20210514A CR20210514A CR20210514A CR20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A
- Authority
- CR
- Costa Rica
- Prior art keywords
- reboxetine
- narcolepsy
- treat narcolepsy
- cataplexy
- treat
- Prior art date
Links
- 201000003631 narcolepsy Diseases 0.000 title abstract 4
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title abstract 4
- 229960003770 reboxetine Drugs 0.000 title abstract 4
- 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se describen métodos para el tratamiento de narcolepsia con cataplexia, que comprenden la administración de reboxetina a un ser humano que lo necesita. La reboxetina también se puede usar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se describen en el presente documento kits que comprenden una composición farmacéutica que comprende reboxetina e instrucciones para usar la composición farmacéutica para tratar la narcolepsia con cataplexia en un ser humano.Described herein are methods for treating narcolepsy with cataplexy, comprising administering reboxetine to a human in need thereof. Reboxetine can also be used to make a drug to treat narcolepsy with cataplexy. Also described herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions for using the pharmaceutical composition to treat narcolepsy with cataplexy in a human.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745956P | 2018-10-15 | 2018-10-15 | |
| PCT/US2019/056134 WO2020081461A1 (en) | 2018-10-15 | 2019-10-14 | Use of reboxetine to treat narcolepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210514A true CR20210514A (en) | 2021-11-12 |
Family
ID=70284075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210514A CR20210514A (en) | 2018-10-15 | 2019-10-14 | Use of reboxetine to treat narcolepsy |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3866768A4 (en) |
| JP (2) | JP2022504975A (en) |
| KR (2) | KR20240119194A (en) |
| CN (1) | CN112888430A (en) |
| AU (3) | AU2019361915A1 (en) |
| BR (1) | BR112021007019A2 (en) |
| CL (1) | CL2021000924A1 (en) |
| CO (1) | CO2021004681A2 (en) |
| CR (1) | CR20210514A (en) |
| EC (1) | ECSP21031200A (en) |
| IL (2) | IL282311B2 (en) |
| MX (2) | MX2021004207A (en) |
| PE (1) | PE20211199A1 (en) |
| SG (1) | SG11202103588WA (en) |
| WO (1) | WO2020081461A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| KR102893312B1 (en) * | 2021-10-19 | 2025-12-01 | 단국대학교 천안캠퍼스 산학협력단 | Composition for preventing or treating sarcopenia comprising reboxetine as an active ingredient |
| WO2025207664A1 (en) * | 2024-03-25 | 2025-10-02 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| AU2002358270A1 (en) * | 2001-12-20 | 2003-07-09 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
| AR040680A1 (en) * | 2002-07-25 | 2005-04-13 | Pharmacia Corp | COMPOSITION OF SUSTAINED RELEASE TABLETS |
| BRPI0511941A (en) * | 2004-06-09 | 2008-01-22 | Pfizer | use of racemic (s, s) reboxetine or reboxetine |
| CA2905457A1 (en) * | 2013-03-13 | 2014-10-09 | Aerial Biopharma, Llc | Treatment of cataplexy |
-
2019
- 2019-10-14 IL IL282311A patent/IL282311B2/en unknown
- 2019-10-14 CR CR20210514A patent/CR20210514A/en unknown
- 2019-10-14 WO PCT/US2019/056134 patent/WO2020081461A1/en not_active Ceased
- 2019-10-14 KR KR1020247025741A patent/KR20240119194A/en active Pending
- 2019-10-14 KR KR1020217013455A patent/KR20210071046A/en not_active Ceased
- 2019-10-14 SG SG11202103588WA patent/SG11202103588WA/en unknown
- 2019-10-14 AU AU2019361915A patent/AU2019361915A1/en not_active Abandoned
- 2019-10-14 MX MX2021004207A patent/MX2021004207A/en unknown
- 2019-10-14 PE PE2021000514A patent/PE20211199A1/en unknown
- 2019-10-14 CN CN201980067756.9A patent/CN112888430A/en active Pending
- 2019-10-14 JP JP2021520615A patent/JP2022504975A/en active Pending
- 2019-10-14 BR BR112021007019-2A patent/BR112021007019A2/en unknown
- 2019-10-14 EP EP19874099.5A patent/EP3866768A4/en active Pending
- 2019-10-14 IL IL319177A patent/IL319177A/en unknown
-
2021
- 2021-04-12 MX MX2025003477A patent/MX2025003477A/en unknown
- 2021-04-14 CO CONC2021/0004681A patent/CO2021004681A2/en unknown
- 2021-04-14 CL CL2021000924A patent/CL2021000924A1/en unknown
- 2021-04-30 EC ECSENADI202131200A patent/ECSP21031200A/en unknown
-
2023
- 2023-02-16 AU AU2023200917A patent/AU2023200917A1/en not_active Abandoned
-
2025
- 2025-02-23 AU AU2025201286A patent/AU2025201286A1/en active Pending
- 2025-06-10 JP JP2025096479A patent/JP2025134749A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019361915A1 (en) | 2021-05-13 |
| JP2025134749A (en) | 2025-09-17 |
| CN112888430A (en) | 2021-06-01 |
| AU2025201286A1 (en) | 2025-03-13 |
| CA3115983A1 (en) | 2020-04-23 |
| KR20240119194A (en) | 2024-08-06 |
| IL282311B1 (en) | 2025-04-01 |
| PE20211199A1 (en) | 2021-07-01 |
| MX2021004207A (en) | 2021-08-11 |
| WO2020081461A1 (en) | 2020-04-23 |
| JP2022504975A (en) | 2022-01-13 |
| MX2025003477A (en) | 2025-05-02 |
| CO2021004681A2 (en) | 2021-06-21 |
| NZ775057A (en) | 2024-09-27 |
| SG11202103588WA (en) | 2021-05-28 |
| BR112021007019A2 (en) | 2021-07-13 |
| CL2021000924A1 (en) | 2021-09-03 |
| KR20210071046A (en) | 2021-06-15 |
| AU2023200917A1 (en) | 2023-03-23 |
| EP3866768A1 (en) | 2021-08-25 |
| IL282311A (en) | 2021-05-31 |
| IL282311B2 (en) | 2025-08-01 |
| ECSP21031200A (en) | 2021-05-31 |
| IL319177A (en) | 2025-04-01 |
| EP3866768A4 (en) | 2022-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210514A (en) | Use of reboxetine to treat narcolepsy | |
| CL2023001949A1 (en) | Antibodies targeting HIV gp120 and methods of use (divisional patent application no. 3422-2020) | |
| CO2022010330A2 (en) | Gamma-Hydroxybutyrate (GHB) Dosage | |
| MX2023000735A (en) | METHODS AND COMBINATIONS OF KAT6 INHIBITOR FOR THE TREATMENT OF CANCER. | |
| BR112016027773A2 (en) | cell penetrating peptide, polynucleotide, recombinant botulinum toxin penetrating cell protein, recombinant expression vector, bacterium, pharmaceutical composition, cosmetic composition and method for producing a recombinant botulinum toxin cell penetrating protein | |
| CL2017002996A1 (en) | Tetra-substituted alkene compounds and their use | |
| GT201700246A (en) | METHODS AND KITS TO TREAT DEPRESSION | |
| MX2019010757A (en) | METHODS AND COMPOSITIONS RELATED TO THE COMBINED TREATMENT WITH ANTI-INFLAMMATORY AND SYNTHETIC NANPORTERS THAT INCLUDE AN IMMUNOSUPPRESSOR. | |
| CL2025001913A1 (en) | Anti-nectin-4 antibody; conjugate comprising it; pharmaceutical composition; and its use. | |
| CL2008001268A1 (en) | Compounds derived from n- [6-amino-5-aryl-pyridin-2-yl] -carboxamide; pharmaceutical composition that includes them; combined pharmaceutical composition comprising them together with another additional pharmacological agent; and use them in the treatment of pain. | |
| AR101312A1 (en) | COMBINATIONS OF BET INHIBITORS AND INHIBITORS OF TIROSINA QUINASA DE BRUTON | |
| MX2022014792A (en) | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF AND TREATMENT METHODS INVOLVING THEM. | |
| MX2019003134A (en) | Combination therapy. | |
| MX2016015437A (en) | COMBINATION THAT INCLUDES A GLUCOCORTICOID AND EDO-S101. | |
| CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
| MX2018016332A (en) | COMBINATION CHEMOTHERAPIES. | |
| MX2024003918A (en) | THERAPEUTIC AGENT THAT INDUCES CYTOTOXICITY FOR USE IN CANCER THERAPY. | |
| MX2022014577A (en) | LEVODOPA AND CARBIDOPA INTESTINAL GEL AND METHODS OF USE. | |
| MX2021003263A (en) | Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer. | |
| MX2022005358A (en) | Ph responsive block copolymer compositions, micelles, and methods of use. | |
| MX2016011025A (en) | GRAPIPRANT COMPOSITIONS AND METHODS TO USE THE SAME. | |
| MX2021011334A (en) | Antibodies having specificity for btn2 and uses thereof. | |
| CL2021003442A1 (en) | Pharmaceutical composition comprising idelalisib and defactinib; and methods for treating cancer. | |
| BR112019004540A2 (en) | method for treating dementia in a patient, pharmaceutical composition, method for treating dementia in a patient, method for reducing the likelihood of developing dementia in a patient, composition for use in treating dementia in a patient, composition and composition for use in reducing dementia likelihood of developing dementia in a patient undergoing long therapy with a non-steroidal anti-inflammatory drug or aspirin | |
| MX2024012392A (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |